Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 9
2018 11
2019 8
2020 5
2021 2
2022 2
2023 3
2024 4
2025 8
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab and new-onset spondyloarthritis: Debunking the myth.
Roseira J, Marafini I, Noor NM. Roseira J, et al. United European Gastroenterol J. 2024 Sep;12(7):830-831. doi: 10.1002/ueg2.12624. Epub 2024 Jul 11. United European Gastroenterol J. 2024. PMID: 38990708 Free PMC article. No abstract available.
The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients.
Huseynzada S, Yüce İnel T, Hajiyev F, Köken Avşar A, Balcı A, Akpınar H, Önen F, Sarı İ. Huseynzada S, et al. Eur J Rheumatol. 2023 Apr;10(2):50-56. doi: 10.5152/eurjrheum.2023.22049. Eur J Rheumatol. 2023. PMID: 37171478 Free PMC article.
We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis. ...The occurrence of new musculoskeletal findings during the vedolizumab treatment was reco …
We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of pa …
Combination targeted therapy with two biologic/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy.
Lignou AZ, Vassilakis KD, Baraliakos X, Sfikakis PP, Gottenberg JE, Fragoulis GE. Lignou AZ, et al. Autoimmun Rev. 2025 Sep 24;24(10):103865. doi: 10.1016/j.autrev.2025.103865. Epub 2025 Jul 7. Autoimmun Rev. 2025. PMID: 40633795 Free article.
BACKGROUND: Immune-mediated inflammatory diseases (IMID) include rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), Crohn's disease (CD), ulcerative colitis (UC), and psoriasis (PsO). ...The most studied combinations were TNFi+IL/23i, JA …
BACKGROUND: Immune-mediated inflammatory diseases (IMID) include rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarth …
Clinical features, pathogenesis, and treatment of inflammatory bowel disease-associated spondyloarthritis.
Akiyama M, Alshehri W, Suzuki K, Shimanuki K, Saito K, Kaneko Y. Akiyama M, et al. Autoimmun Rev. 2025 Aug 29;24(9):103853. doi: 10.1016/j.autrev.2025.103853. Epub 2025 Jun 15. Autoimmun Rev. 2025. PMID: 40527403 Review.
Inflammatory bowel disease-associated spondyloarthritis (IBD-SpA) is a unique subtype of SpA that affects approximately 10-20 % of patients with IBD. ...Among the available therapeutic options, TNF inhibitors and JAK inhibitors have demonstrated efficacy in both IBD and Sp …
Inflammatory bowel disease-associated spondyloarthritis (IBD-SpA) is a unique subtype of SpA that affects approximately 10-20 % of pa …
The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Zheng DY, Wang YN, Huang YH, Jiang M, Ma YN, Dai C. Zheng DY, et al. J Gastroenterol Hepatol. 2024 Sep;39(9):1745-1759. doi: 10.1111/jgh.16612. Epub 2024 May 13. J Gastroenterol Hepatol. 2024. PMID: 38740543
BACKGROUND AND AIM: Extraintestinal manifestations (EIMs) pose a significant threat in inflammatory bowel disease (IBD) patients. Vedolizumab (VDZ) primarily affects the gastrointestinal tract. However, its impact on EIMs remains uncertain. ...CONCLUSION: VDZ demonstrates …
BACKGROUND AND AIM: Extraintestinal manifestations (EIMs) pose a significant threat in inflammatory bowel disease (IBD) patients. Vedoliz …
The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review.
Nardone OM, Noor NM, Prabhu A, Lim A, Krishnakumar A, Alajmi A, Yuan Y, Jairath V, Estevinho MM, Solitano V. Nardone OM, et al. Aliment Pharmacol Ther. 2025 Jun;61(12):1854-1871. doi: 10.1111/apt.70181. Epub 2025 May 6. Aliment Pharmacol Ther. 2025. PMID: 40329548 Free PMC article.
The lowest improvement was in patients treated with vedolizumab for joint manifestations. Ustekinumab was effective for arthralgia and psoriatic arthritis, but not for axial spondylarthritis. High heterogeneity of response was reported for anti-TNF, vedolizumab …
The lowest improvement was in patients treated with vedolizumab for joint manifestations. Ustekinumab was effective for arthralgia an …
Triple biologic therapy for refractory Crohn's disease.
Vieujean S, Peyrin-Biroulet L. Vieujean S, et al. J Crohns Colitis. 2025 May 8;19(5):jjaf067. doi: 10.1093/ecco-jcc/jjaf067. J Crohns Colitis. 2025. PMID: 40251965 Free article.
Despite multiple lines of therapy, including, anti-tumor necrosis factor agents, vedolizumab, ustekinumab, and upadacitinib, both CD and ankylosing spondylitis remained clinically active. In the absence of alternative therapeutic options and continued refusal of surgery, a …
Despite multiple lines of therapy, including, anti-tumor necrosis factor agents, vedolizumab, ustekinumab, and upadacitinib, both CD …
44 results